This study tests the hypothesis that montelukast sodium, a selective leukotriene receptor antagonist, will decrease the duration of the effusion of otitis media. Tympanometry and spectral gradient acoustic reflectometry were used to confirm the effusion of otitis media in patients between 2 and 12 years of age. Patients were treated with amoxicillin for 10 days and montelukast sodium or placebo for 30 days in a random, double-blind manner. Sixty patients completed the study: 31 received placebo and 29 received montelukast sodium. At a 4-week follow-up visit, 5 ears (16%) were free of effusion in the placebo group and 17 (58%) in the montelukast sodium group. The difference was significant. The efficacy of montelukast sodium in clearing the effusion was 49%.
Get full access to this article
View all access options for this article.
References
1.
Shurin PA, Pelton SI, Klein JO. Persistence of middle-ear effusion after acute otitis media in children. N Engl J Med. 1979;300:1121-1123.
2.
Teele DW, Klein JO, Rosner BA. Epidemiology of otitis media in children. Ann Otol Rhinol Laryngol. 1980;89:5-6.
3.
Green LA, Culpepper L, deMelker RA, et al.Tympanometry interpretation by primary care physicians: a report from the international primary care network and the ambulatory sentinel practice network. J Fam Pract. 2000;49:932-936.
4.
Kontiokari T, Niemela M, Uhari M. Middle ear effusion among children diagnosed and treated actively for acute otitis media. Eur J Pediatr. 1998;157:731-734.
5.
Sakaguchi M, Taguchi K, Ishiyama Y, et al.Tympanometric changes following acute otitis media in Japanese children. Eur Arch Oto-Rhinol-Laryngol. 1994;251:113-116.
6.
Spremo S, Marki Z, Kurbalija. Clinical importance of tympanometry in the diagnosis of chronic secretory otitis. Srpski Arhiv Za Celokupno Lekarstvo. 1998;126:242-247.
7.
Zielhuis GA, Rach GH, van den Broek P. The natural course of otitis media with effusion in preschool children. Eur Arch Oto-Rhinol-Laryngol. 1990;247:215-221.
8.
Vartianen E, Kansanen M, Vartianen J. The contralateral ear in patients with chronic otitis media. Am J Otol. 1996;17:190-192.
9.
Gates GH. Cost-effectiveness considerations in otitis media treatment. In: Lim DJ, Bluestone CD, Casselbrant M, et al, eds. Proceedings of the Sixth International Symposium on Recent Advances in Otitis Media. Hamilton, Canada: DC Decker Inc; 1996:1-4.
10.
Bernstein JM. Otitis media. In: Middleton E Jr, Reed CE, Ellis EF, et al, eds. Allergy Principles and Practice, 4th ed.St Louis: Mosby; 1993:1471-1487.
11.
Barnes PJ. Pathophysiology of allergic inflammation. In: Middleton E Jr, Reed, CE, Ellis EF, et al, eds. Allergy Principles and Practice, 4th ed. St Louis: Mosby; 1993:243-266.
12.
Jung TT. Prostaglandins, leukotrienes, and other arachidonic acid metabolites in the pathogenesis of otitis media. Laryngoscope. 1988;980:93.
13.
Brodsky L, Faden H, Bernstein J, et al.Arachidonic acid metabolites in middle ear effusion in children. Ann Otol Rhinol Laryngol. 1991;100:589-592.
14.
Sutbeyaz Y, Yakan B, Ozdemir H, et al.Effect of SC-41930, a potent leukotriene B4 receptor antagonist, in the guinea pig model of middle ear inflammation. Ann Otol Rhinol Laryngol. 1996;105:486-490.
15.
Ganbo T, Hisamatsu K, Shimomura S, et al.Inhibition of mucociliary clearance of the Eustachian tube by leukotrienes C4 and D4. Ann Otol Rhinol Laryngol. 1995;104:231-236.
16.
Enomoto F, Ichikawa G, Nagaoka I, Yamashita T. Measurement of leukotrienes C4 and D4 in the effusion of otitis media. In: Mogi G, Honjo I, Ishii T, eds. Recent Advances in Otitis Media. Proceedings of the Second Extraordinary International Symposium. Otia, Japan; Amsterdam, Netherlands: Kugler Publications; 1994:655-659.
17.
Maron ZVI, Shelhamer JH, Bach MK, et al.Slow-reaction substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis. 1982;126:449-451.
18.
Bisgaad H, Pederson M. SRS-A leukotrienes decrease the activity of human respiratory cilia. Clin Allergy. 1987:17:95-103.
19.
Tachibana F, Shimada T, Hori Y, et al.Platelet activation factor and leukotrienes in acute otitis media, secretory otitis media and chronic otitis media on the acute exacerbation. Auris Nasus Larynx. 1996;23:20-25.
20.
Lee SH, Woo HW, Jung TT, et al.Permeability of arachidonic acid metabolites through the round window membrane in chinchillas. Acta Otolaryngol Supp (Stockh). 1992;493:165-169.
21.
Chonmaitree T, Patel JA, Sim T, et al.Role of leukotriene B4 and interleukin-8 in acute bacterial and viral otitis media. Ann Otol Rhinol Laryngol. 1996;105:968-974.
Dubreuil C. [Inflammation and acute otitis media.] [French] Presse Med. 2001;30:19-25.
24.
van Adelsberg J, Philip G, LaForce CR, et al.Randomized controlled trial evaluating the clinical benefit of montelukast sodium for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003;90:214-222.
25.
Combs JT. The diagnosis of otitis media: new technologies. Pediatr Infect Dis J. 1994;13:1039-1049.
26.
Watters GW, Jones JE, Freeland AP. The predictive value of tympanometry in the diagnosis of middle ear effusion. Clin Otolarygol Allied Sci. 1997;22:343-345.
27.
Palmu A, Puhakka H, Rahko T, Takala AK. Diagnostic value of tympanometry in infants in clinical practice. Int J Pediatr OtoRhinolaryngol. 1999;49:207-213.
28.
Block SL, Pichichero ME, McLinn S, et al.Spectral gradient acoustic reflectometry: detection of middle ear effusion in suppurative acute otitis media. Pediatr Infect Dis J. 1999;18:741-744.
29.
Kemalolu YK, Sener T, Beder L, et al.Predictive value of acoustic reflectometry (angle and reflectivity) and tympanometry. Int J Pediatr OtoRhinolaryngol. 1999;48:137-142.
30.
Bodor FF, Marchant CD, Shurin PA, Barenkamp SJ. Bacterial etiology of conjunctivitis media syndrome. Pediatrics. 1985;76:26-28.
31.
Klein JO. Management of otitis media: 2000 and beyond. Pediatr Infect Dis J. 2000;19:383-387.
32.
Fireman P. Otitis media and Eustachian tube dysfunction: connection to allergic rhinitis. J Allergy Clin Immunol. 1997;99:S787-S797.
33.
Sigurs N, Hattevig G, Kjellman B, et al.Appearance of atopic disease in relation to serum IgE antibodies in children followed up from birth to 4 to 15 years. J Allergy Clin Immunol. 1994;94:757-763.
